Gene
POMC
POMC is a gene biomarker in the evidence tier "FDA companion diagnostic". This page lists evidence by type: FDA companion diagnostic assertions (1), Assay-provider ledger (11), Trial mentions (288), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
FDA companion diagnostic
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention POMC. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with a planned future start.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 61 dated before 1990 and 39 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 11 of 8,738 | 0.13% | not measured | |
| 2025 | 18 of 8,875 | 0.20% | not measured | |
| 2024 | 19 of 8,597 | 0.22% | not measured | |
| 2023 | 17 of 8,275 | 0.21% | 117 of 11,460 | 1.02% |
| 2022 | 16 of 8,285 | 0.19% | 124 of 13,598 | 0.91% |
| 2021 | 20 of 8,692 | 0.23% | 159 of 15,045 | 1.06% |
| 2020 | 10 of 7,640 | 0.13% | 161 of 14,459 | 1.11% |
| 2019 | 13 of 7,300 | 0.18% | 124 of 12,159 | 1.02% |
| 2018 | 16 of 6,927 | 0.23% | 111 of 11,854 | 0.94% |
| 2017 | 13 of 6,558 | 0.20% | 141 of 11,595 | 1.22% |
Showing 10 of 37 years.
FDA companion diagnostic assertions (1)
Shown in this order: most recent decision first.
| Diagnostic | Source biomarker wording | Manufacturer | Indication | Decision date |
|---|---|---|---|---|
| POMC/PCSK1/LEPR CDx Panel | POMC | PreventionGenetics, LLC | Obesity | 2022-01-21 |
Assay-provider ledger (11)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Bostonchem, USA | Reagent supplier | Clinical validation | 1 | October 18, 2024 |
| Agilent Technologies | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | May 07, 2021 |
| Applied Biosystems, ThermoFisher Scientific | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | May 07, 2021 |
| BIO-RAD Laboratories S.A. (trypan blue) | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | May 07, 2021 |
| Millipore | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | May 07, 2021 |
Showing 5 of 11 assay-provider companies.
Trial mentions (288)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT01912833 | Trial biospecimen (AACT) |
| NCT02133963 | Trial biospecimen (AACT) |
| NCT02299921 | Trial biospecimen (AACT) |
| NCT07003334 | Trial biospecimen (AACT) |
| NCT03745651 | Trial eligibility (AACT) |
Showing 5 of 288 trial mentions.
Target-disease associations (673)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 46,XX testicular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| 46,XY complete gonadal dysgenesis | cardiovascular disease | Mouse knockout (IMPC) |
| ACTH Syndrome, Ectopic | cancer or benign tumor | Literature (Europe PMC) |
| ACTH-Producing Pituitary Gland Adenoma | cancer or benign tumor | Literature (Europe PMC) |
| ACTH-independent Cushing syndrome | endocrine system disease | Literature (Europe PMC) |
Showing 5 of 673 associations.
Vendor sourcing (758)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is observed at an extremely low frequency in the gnomAD v4.1.0 dataset (total allele frequency: <0.001%). Predicted Consequence/Location: Stop-ga... | View ClinVar record SCV007607069.1 |
| AIM ImmunoTech Inc. | Trial collaborator | Named in trial exclusion criteriaTrial eligibility criteria | : * Patients who have an active autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus (SLE), ulcerative colitis, Crohn's Disease, mult... | View trial NCT02432378 |
| AIM ImmunoTech Inc. | Trial collaborator | Named in trial exclusion criteriaTrial eligibility criteria | : 1. Patients with sarcoma. 2. Patients who have an active autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus (SLE), ulcerative co... | View trial NCT07634094 |
| AIM ImmunoTech Inc. | Trial collaborator | Mentioned in trial textTrial free-text mention | Adrenocorticotropic hormone | View trial NCT02432378 |
| AIM ImmunoTech Inc. | Trial collaborator | Mentioned in trial textTrial free-text mention | Adrenocorticotropic hormone | View trial NCT07634094 |
Showing 5 of 758 sourcing records.
Trial-cited literature (2,158)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Blunted arginine vasopressin secretion in individuals experiencing a major depressive episode with comorbid post-traumatic stress disorder: Results from an exploratory study using copeptin as a surrogate marker. | Journal of neuroendocrinology | 2026 | 0 |
| Setmelanotide in patients aged 2-5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial. | The lancet. Diabetes & endocrinology | 2025 | 37 |
| Advances in GLP-1 receptor agonists for pain treatment and their future potential. | The journal of headache and pain | 2025 | 19 |
| Low-Dose Hydrocortisone in Cirrhotic Patients With Septic Shock: A Double-Blind Randomised Placebo-Controlled Trial. | Liver international : official journal of the International Association for the Study of the Liver | 2025 | 7 |
| Neurophysiological Effects of Dry Needling: A Systematic Review and Meta-analysis. | Archives of physical medicine and rehabilitation | 2025 | 5 |
Showing 5 of 2,158 papers.
Protein variant mentions (61)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A164V | 1 | 2015 | PMID 25741868 |
| p.A195T | 1 | 2015 | PMID 25741868 |
| p.A2M | 1 | 2009 | PMID 19789384 |
| p.C28* | 1 | 2015 | PMID 25741868 |
| p.D727E | 1 | 2020 | PMID 32349628 |
Showing 5 of 61 variants.
Literature-extracted relations (516)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| (A)Bismuth | Chemical | associate |
Safety and efficacy of alcohol-mediated bilateral adrenal artery embolization in patients with idiopathic hyperaldosteronism: a 6-month follow-up of a randomized controlled trial. | 2025 |
| Dextromethorphan | Chemical | associate |
Cortisol and ACTH response to Dex/CRH testing and 24-hour urine free cortisol levels in women with and without premenstrual dysphoric disorder. | 2025 |
| "Hydrocortisone" | Chemical | positive_correlate |
Utility of Adrenal Vein Sampling With and Without Ultra-Low Dose ACTH Infusion in the Diagnostic Evaluation of Primary Aldosteronism. | 2024 |
| Aldosterone | Chemical | positive_correlate |
Utility of Adrenal Vein Sampling With and Without Ultra-Low Dose ACTH Infusion in the Diagnostic Evaluation of Primary Aldosteronism. | 2024 |
| Sertraline | Chemical | positive_correlate |
Luteal phase sertraline treatment of premenstrual dysphoric disorder (PMDD): Effects on markers of hypothalamic pituitary adrenal (HPA) axis activation and inflammation. | 2024 |
Showing 5 of 516 relation assertions.
Organizations publishing (984)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 101 | 1991 to 2026 |
| Mass General Brigham | Hospital | 46 | 1999 to 2024 |
| Harvard Medical School | Academic | 36 | 1990 to 2024 |
| Mayo Clinic | Hospital | 30 | 2013 to 2024 |
| University of Michigan | Academic | 29 | 1993 to 2024 |
Showing 5 of 984 organizations.
Where POMC appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- medical procedure
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- psychiatric disorder
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
639 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda biomarker qualification projects, actionable biomarkers, and human sample screening reference.